Aptinyx Inc (APTX) Expected to Post Quarterly Sales of $1.10 Million

Aptinyx logo Wall Street analysts predict that Aptinyx Inc (NASDAQ:APTX) will announce $1.10 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Aptinyx’s earnings. The highest sales estimate is $1.20 million and the lowest is $1.00 million. The business is scheduled to issue its next quarterly earnings report on Tuesday, February 12th.

According to Zacks, analysts expect that Aptinyx will report full year sales of $6.37 million for the current financial year, with estimates ranging from $6.00 million to $6.74 million. For the next year, analysts expect that the business will report sales of $4.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Tuesday, November 13th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.58. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $1.10 million.

Separately, Cantor Fitzgerald started coverage on shares of Aptinyx in a report on Wednesday, November 14th. They issued an “overweight” rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $34.25.

Shares of APTX stock traded down $13.05 on Friday, hitting $4.78. The stock had a trading volume of 3,610,573 shares, compared to its average volume of 138,002. Aptinyx has a 12-month low of $15.01 and a 12-month high of $32.25.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Aptinyx during the third quarter valued at about $58,000. Vanguard Group Inc grew its position in Aptinyx by 371.0% during the third quarter. Vanguard Group Inc now owns 296,717 shares of the company’s stock valued at $8,593,000 after buying an additional 233,717 shares during the period. Vanguard Group Inc. grew its position in Aptinyx by 371.0% during the third quarter. Vanguard Group Inc. now owns 296,717 shares of the company’s stock valued at $8,593,000 after buying an additional 233,717 shares during the period. TIAA CREF Investment Management LLC bought a new position in Aptinyx during the third quarter valued at about $775,000. Finally, Teachers Advisors LLC bought a new position in Aptinyx during the third quarter valued at about $515,000. Institutional investors own 64.76% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Recommended Story: Backdoor Roth IRA

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *